SLGL

Insider Trades

Name	Value	Action	Price	Current Price
Opaleye Management Inc.10 Percent Owner $101k1.6k shares BuyMay 20, 2026 $64.43 --
Opaleye Management Inc.10% Owner $101k1.6k shares BuyMay 20, 2026 $64.43 --
Opaleye Management Inc.10 Percent Owner $130k1.9k shares BuyMay 13, 2026 $66.87 --
Opaleye Management Inc.10 Percent Owner $102k1.5k shares BuyMay 12, 2026 $67.98 --
Opaleye Management Inc.10 Percent Owner $2.5M34.7k shares BuyMar 24, 2026 $72.00 --
Opaleye Management Inc.10 Percent Owner $360k5k shares BuyMar 24, 2026 $72.00 --

News

zacks.comSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 28

globenewswire.comSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.comMay 28

globenewswire.comSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offeringglobenewswire.comMar 23

Trade SLGL

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

CEO: Moshe Arkin
IPO Date: Feb 1, 2018

Market Data

Open: $71.57
High: $74.95
Low: $69.54
Volume: 17.5K
Avg Volume: 42.8K
52W High: $97.97
52W Low: $6.96

Valuation

Market Cap: $209M
Enterprise Value: $200M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $275k
Revenue: $19M
Net Income: $-6.1M
Cash: $11M
Debt: $991k

Events

EarningsAug 21

EPS est. -3.33